Rockwell Medical ( (RMTI) ) has released its Q2 earnings. Here is a breakdown of the information Rockwell Medical presented to its investors.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Rockwell Medical, Inc. is a healthcare company specializing in the development, manufacture, and distribution of hemodialysis products for dialysis providers worldwide. The company is known for its commitment to high-quality products and excellent customer service.
In its second quarter 2025 earnings report, Rockwell Medical announced a cash flow generation of $1.8 million from operations, maintaining a gross margin of 16%. Despite a decrease in net sales and gross profit due to the transition of its largest customer to another supplier, the company increased its cash position to $18.4 million.
Key financial metrics for the second quarter of 2025 include net sales of $16.1 million, a 38% decrease from the previous year, and a net loss of $1.5 million compared to a net income of $0.3 million in the same period of 2024. The company’s adjusted EBITDA showed a slight improvement from the first quarter of 2025, standing at ($0.2) million.
Strategically, Rockwell Medical secured several new product purchase agreements with major healthcare providers, reinforcing its market position. More than 80% of its customers are now under long-term contracts, which is expected to support future growth.
Looking ahead, Rockwell Medical remains focused on enhancing its product offerings and operational efficiency. The company confirms its 2025 annual guidance, anticipating net sales between $65.0M to $70.0M and a gross margin of 16% to 18%, aiming for improved profitability on an adjusted EBITDA basis.